Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Mar 2, 2024
Discovery & Translation
Science spotlight: Doudna lab’s cell-penetrating CRISPR RNPs, durable epigenome editing and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 15, 2023
Distillery Therapeutics
Nanozyme for continuous production of dopamine in Parkinson’s disease
BioCentury | Feb 25, 2021
Deals
Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more
ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH) in a cash and stock transaction valued at about $12 billion. The deal combines ICON’s Accellacare site
BioCentury | Jun 27, 2019
Product Development
Gene therapy’s next frontier lies beyond rare, monogenic diseases
How gene therapy is transitioning from single gene disorders to a modality of general use
BioCentury | Feb 1, 2019
Product R&D
BlueRock’s PD purity play
Why BlueRock’s iPS cells could fare better in Parkinson’s than fetal transplants
Items per page:
1 - 10 of 20